From: "Terry E. Pearson" <tpearsonaz@baraboo-bengals.co.uk>
To: <paliourg@iit.demokritos.gr>
Subject:  Strong Buy Alert: Weekly Member Newsletter
Date: Thu, 6 May 2004 09:28:15 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<html>

<head>
<meta http-equiv=3D"Content-Language" content=3D"en-us">
<meta http-equiv=3D"Content-Type" content=3D"text/html; =
charset=3Dwindows-1252">
<title>Gotham Financial Daily</title>
</head>

<body>

<div id=3D"messageBody">
	<p align=3D"center"><b><font face=3D"Arial" size=3D"5" =
color=3D"#000080">Gotham=20
	Financial</font><font lang=3D"0" face=3D"Arial" color=3D"#000080" =
size=3D"5"> Daily</font></b><font lang=3D"0" face=3D"Arial" =
color=3D"#000000" size=3D"3"><br>
&nbsp;</font></p>
	<p align=3D"center"><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"3"><b>
	BioElectronics Corp.</b></font></p>
	<p align=3D"center"><b><font face=3D"Arial">(OTC PINK SHEETS: =
BIEL)</font></b><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"3"><br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">&nbsp;</font></p>
	<p align=3D"left"><b><font face=3D"Arial" size=3D"2" =
color=3D"#800000">**MEGA=20
	TRADING ALERT**</font></b></p>
	<p align=3D"left"><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2"><b>
	SPECIAL-ALERT-</b></font><b><font lang=3D"0" face=3D"Arial" size=3D"2" =
color=3D"#800000">BIEL.PK</font><font lang=3D"0" face=3D"Arial" =
color=3D"#000000" size=3D"3"><br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">Check out the=20
	gains from recent </font>
	<font lang=3D"0" face=3D"Arial" color=3D"#800000" =
size=3D"2">strong-buy</font><font lang=3D"0" face=3D"Arial" =
color=3D"#000000" size=3D"2">=20
	recommendations...</font><font lang=3D"0" face=3D"Arial" =
color=3D"#000000" size=3D"3"><br>
	<br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">December?HTSC at=20
	.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High =
3.25....</font><font lang=3D"0" face=3D"Arial" color=3D"#008040" =
size=3D"2">410%=20
	Gain! </font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2"><br>
	January?...QLHC at&nbsp; 90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
High 3.50....</font><font lang=3D"0" face=3D"Arial" color=3D"#008040" =
size=3D"2">389%=20
	Gain! </font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2"><br>
	April&nbsp;??.....IPYS at =
.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High =
1.10.....</font><font lang=3D"0" face=3D"Arial" color=3D"#008040" =
size=3D"2">266%=20
	in two days </font><font lang=3D"0" face=3D"Arial" color=3D"#008040" =
size=3D"3">&nbsp;&nbsp;&nbsp;&nbsp;
	</font></b></p>
	<p align=3D"left"><b><font face=3D"Arial" color=3D"#008040">These types =
of gains=20
	happen every day in the world of Pink sheets!&nbsp; Lets look at =
today's=20
	featured company: Bioelectronics Corp.</font><font lang=3D"0" =
face=3D"Arial" color=3D"#000000" size=3D"3"><br>
	<br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">Bioelectronics=20
	Corp: </font><font lang=3D"0" face=3D"Arial" color=3D"#800000" =
size=3D"2">BIEL&nbsp;
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2"><br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#008040" =
size=3D"2">Current-Price:=20
	$0.80&nbsp; <br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =
<br>
	</font></b><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"3"><br>
	</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">Reasons to buy
	</font><b><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2">BIEL.PK :&nbsp;</font></b><font lang=3D"0" face=3D"Arial" =
color=3D"#000000" size=3D"2">BIEL=20
	(Bioelectronics Corporation) is taking proven medical technologies and=20
	making them available to more people in new convenient, cost-effective=20
	dermal patches.&nbsp; By applying advanced microelectronic technology,=20
	Bioelectronics is dramatically reducing the size and the cost of some=20
	well-establ<br>
	<br>
	<b>BIEL</b> first FDA cleared product, ACTIPATCH (TM) therapy is a =
dermal=20
	patch with an embedded microchip that delivers weeks of continuous =
pulsed=20
	electromagnetic energy.&nbsp; ActiPatch therapy is the miniaturized=20
	equivalent of the large pulsed electromagnetic energy machines =
prescribed by=20
	physicians for decades to reduce swelling, relieve pain and enhance the =

	healing of surgical incisions, accidental wounds, sprains, strains and=20
	chronic wounds (bedsores).&nbsp; ActiPatch's size, portability, ease of =
use=20
	and relatively low price overcomes the obstacles to use associated with =
the=20
	large, expensive, stationary machines.&nbsp; The introduction of =
ActiPatch=20
	provides an immediate therapeutic alternative for the 200 million =
surgical=20
	and non-surgical soft tissue injuries across the U.S. annually.&nbsp;=20
	BioElectronics has launched it's ActiPatch product line in cooperative=20
	distribution relationships with several well-established medical device =

	companies in various medical market segments.<br>
&nbsp;</font></p>
	<p align=3D"left"><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"2"><b>New=20
	Products and Additional Applications: BIEL </b>and leading =
pharmaceutical=20
	and device manufacturers and conducting new clinical trials.&nbsp; =
These=20
	trials include: Abdominoplasty -- pain; Face and Forehead Lifts -- pain =
and=20
	edema, Facial Fat Injections -- pain and edema; Heel -- pain and =
healing;=20
	Oral Surgery -- pain; Swelling and accelerated healing; and Abdominal=20
	Surgery -- pain and accelerated healing.&nbsp; Successful results in =
these=20
	trials will be published and used to secure additional FDA approved=20
	indications of use.&nbsp; </font></p>
	<p align=3D"left"><font face=3D"Arial" size=3D"2"><b>BIEL </b>is =
developing=20
	products for the treatment of chronic pain, arthritis, inflammatory =
skin=20
	conditions, and chronic wounds.</font><font lang=3D"0" face=3D"Arial" =
color=3D"#000000" size=3D"3"><br>
	&nbsp;</font><font lang=3D"0" face=3D"Arial" color=3D"#000000" =
size=3D"1"><br>
	<br>
&nbsp;</p>
	<div id=3D"messageBody0">
		Information within this email contains &quot;forward looking =
statements&quot;=20
		within the meaning of Section 27A of the Securities Act of 1933 and=20
		Section 21B of the Securities Exchange Act of 1934. Any statements =
that=20
		express or involve discussions with respect to predictions, goals,=20
		expectations, beliefs, plans, projections, objectives, assumptions or=20
		future events or performance are not statements of historical fact and =

		may be &quot;forward looking statements.&quot; <br>
		<br>
		Forward looking statements are based on expectations, estimates and=20
		projections at the time the statements are made that involve a number =
of=20
		risks and uncertainties which could cause actual results or events to=20
		differ materially from those presently anticipated. Forward looking=20
		statements in this action may be identified through the use of words=20
		such as: &quot;projects&quot;, &quot;foresee&quot;, =
&quot;expects&quot;, &quot;estimates,&quot; &quot;believes,&quot;=20
		&quot;understands&quot; &quot;will&quot;, &quot;anticipates,&quot; or =
that by statements indicating=20
		certain actions &quot;may,&quot; &quot;could,&quot; or =
&quot;might&quot; occur. All information=20
		provided within this email pertaining to investing, stocks, securities =

		must be understood as information provided and not investment advice. =
WE=20
		advise all readers and subscribers to seek advice from a registered=20
		professional securities representative before deciding to trade in=20
		stocks featured within this email. None of the material within this=20
		report shall be construed as any kind of investment advice. GS =
Research=20
		and/or its officers and employees have been compensated $10,000.00 =
cash=20
		by a third party for work involved in the preparation and production =
of=20
		this report<p>In compliance with Section 17(b), we disclose the =
holding=20
		of independently purchased shares of the company mentioned prior to =
the=20
		publication of this report.. Be aware of an inherent conflict of=20
		interest resulting from such holdings due to our intent to profit from =

		the liquidation of these shares. Shares may be sold at any time, even=20
		after positive statements have been made regarding the above company.=20
		Short term trading targets are only guesses on our part. Keep in mind=20
		that when trading small stocks like the company above there is a =
chance=20
		you will lose every penny you invest. Furthermore there have been =
times=20
		in the past when the Company itself tells lies, gives false =
information=20
		and puts out false news. This email is for entertainment purposes =
only.=20
		This is not investment advice. We suggest you check with an investment =

		professional before investing any stocks or mutual funds.<br>
&nbsp;</div>
	<meta http-equiv=3D"pragma" content=3D"no-cache">
	<meta http-equiv=3D"cache-control" content=3D"no-cache">
	<meta http-equiv=3D"expires" content=3D"Sun, 21 Mar 1999 06:05:29 GMT">
<SCRIPT language=3Djavascript>
   if(top.MLRead) =20
     top.MLRead._messageLoaded();
</SCRIPT>
	<p>&nbsp;</font></div>

</body>

</html>
